

**AXIOM**



# Using CDM and NDC Profile Filters

| December 14, 2017

# What are Charge Code Profile Filters?

- Peak can now pull all encounters that had a selected charge item
  - During periodic CDM review, you can see every patient that received a specific charge
  - Peak's advantage is the ability to roll up all patients that had the charge
  - This allows for a cost/benefit analysis of charge items
  - It also allows for a unique look into the outcome results that charges helped to influence

# Mayo Clinic's Unusual Challenge: Overhaul a Business That's Working

- Summary

- During turning point, CEO turned down request for two new operating rooms
- Instead, focused on cutting costs
- Highest cost variability was found in heart procedures
- Began with reducing operating room time to yield a higher turnover
  - Friendly competition
  - Created conversation on how to lower times
- Found large variability in cost from the heart valves that physicians used
- To allow for purchasing power, restricted physicians to using heart valves from two vendors
- Core to this initiative was protecting Mayo's ability to take on complex cases

# Citation

- Winslow, R. (2017, June 02). Mayo Clinic's Unusual Challenge: Overhaul a Business That's Working. *Wall Street Journal*. Retrieved October 10, 2017, from <https://www.wsj.com>



Go to Peak

# Knee Systems

## KNEE SYSTEMS

Manufacturer	Standard	High-Flex	Revision	Other	Cementless	PSI	UKA
<b>DePuy</b>	Sigma <sup>®</sup>	Attune <sup>®</sup>	TC3 <sup>®</sup> ; S-ROM <sup>®</sup> Noiles™;	LCS <sup>®</sup> (rotating platform)	Duofix	Trumatch <sup>®</sup> (CT-based)	Attune <sup>®</sup>
<b>Smith &amp; Nephew</b>	Genesis II <sup>®</sup>	Journey II <sup>®</sup>	Legion <sup>®</sup>	Journey XR <sup>®</sup> (bicruciate retain)		Visionaire™ (MRI-based)	ZUK <sup>®</sup> , Journey II <sup>®</sup>
<b>Stryker</b>	Triathlon <sup>®</sup>	Scorpio NRG <sup>®</sup>	Triathlon TS <sup>®</sup>		Triathlon <sup>®</sup> Tritanium; Duracon	Mako (CT, Robot)	Triathlon <sup>®</sup>
<b>Biomet</b>	Vanguard <sup>®</sup>	Vanguard <sup>®</sup>	Vanguard 360 <sup>®</sup>	Vanguard XP <sup>®</sup> (bicruciate retain)	Vanguard PPS Femur, Regenerex Tibia; AGC	Signature™ (CT or MRI)	Oxford <sup>®</sup>
<b>Zimmer</b>	NexGen <sup>®</sup>	Persona <sup>®</sup>	NexGen CCK, Zimmer ® Segmental	Gender Solutions <sup>®</sup> Natural Knee	NexGen <sup>®</sup> Tantalum	Persona <sup>®</sup> PSI (CT-based)	M/G High Flex

# Knee Device Minutes Table's

Triath Charge/Device	Vangaurd Charge/Device
\$4,178	\$8,793

Facility	TRIATH Device OR Time	VANGAURD Device OR Time
Lupulin	127 min	na
Bernardus	119 min	na
Archer	na	108 min
Victorius	na	188 min

# What are NDC Profile Filters?

- Peak can now pull all encounters that had a selected NDC code
  - National Drug Code
  - Peak's advantage is the ability to roll up all patients that were given specific drugs
  - This allows for a cost/benefit analysis of the drugs on patients
  - It also allows for a unique look into the outcome results that the drug prescription helped to influence

# IV Acetaminophen Articles

- Summary
  - IV Acetaminophen is expensive
  - Using in combination with narcotics can lead to a decrease in narcotics use
  - Decreasing narcotics use can have these benefits:
    - Decreased amount of patients having respiratory depression
    - Decreased amount of patients with delirium
    - Decreased LOS
    - Less falls in the hospital
    - Decrease in gastrointestinal issues
      - Nausea
      - Vomiting
      - Constipation/Ileus
  - Do benefits outweigh the costs of IV Tylenol

# Citations

- Apfel, C. C., Turan, A., Souza, K., & Pergolizzi, J. (2012). Intravenous acetaminophen reduces postoperative nausea and vomiting: A systematic review and meta-analysis [Abstract]. IASP. Retrieved October 17, 2017, from [dx.doi.org/10.1016/j.pain.2012.12.025](https://doi.org/10.1016/j.pain.2012.12.025).
- Harrington, D., MD. (n.d.). IV Acetaminophen: The Hospitalists Perspective (pp. 1-8, Today's Hospitalist Special Report).

Go to Peak

# Pharmacy Master Scorecards

<b>Pharmacological Class</b>	Anti Convulsants						
<b>Generic Drug Name</b>	CARBAMAZEPINE				FELBAMATE		
<b>NDC Drugs</b>	Carbratrol	Tegretol	Epitol	Atretol	Felbatol	Felbamate	

# Thank You!

- Please reach out to [peaksupport@syntellis.com](mailto:peaksupport@syntellis.com) or (847) 441-0022 if you have further questions.
- A recorded version of this webinar will be available within Peak documentation.
- Webinar Requests?

#### Qualifications, Assumptions and Limiting Conditions (v.12.08.06):

This Report is not intended for general circulation or publication, nor is it to be used, reproduced, quoted or distributed for any purpose other than those that may be set forth herein without the prior written consent of Syntellis Performance Solutions, LLC.

All information, analysis and conclusions contained in this Report are provided “as-is/where-is” and “with all faults and defects”. Information furnished by others, upon which all or portions of this report are based, is believed to be reliable but has not been verified by Syntellis Performance Solutions, LLC. No warranty is given as to the accuracy of such information. Public information and industry and statistical data, including without limitation, data are from sources Syntellis Performance Solutions, LLC deems to be reliable; however, neither Syntellis Performance Solutions, LLC nor any third party sourced make any representation or warranty to you, whether express or implied, or arising by trade usage, course of dealing, or otherwise. This disclaimer includes, without limitation, any implied warranties of merchantability or fitness for a particular purpose (whether in respect of the data or the accuracy, timeliness or completeness of any information or conclusions contained in or obtained from, through, or in connection with this report), any warranties of non-infringement or any implied indemnities.

The findings contained in this report may contain predictions based on current data and historical trends. Any such predictions are subject to inherent risks and uncertainties. In particular, actual results could be impacted by future events which cannot be predicted or controlled, including, without limitation, changes in business strategies, the development of future products and services, changes in market and industry conditions, the outcome of contingencies, changes in management, changes in law or regulations. Syntellis Performance Solutions, LLC accepts no responsibility for actual results or future events.

The opinions expressed in this report are valid only for the purpose stated herein and as of the date of this report.

All decisions in connection with the implementation or use of advice or recommendations contained in this report are the sole responsibility of the client.

In no event will Syntellis Performance Solutions, LLC or any third party sourced by Syntellis Performance Solutions, LLC be liable to you for damages of any type arising out of the delivery or use of this Report or any of the data contained herein, whether known or unknown, foreseeable or unforeseeable.

10 S. Wacker, Suite 3375, Chicago, Illinois 60606-4720  
[www.syntellis.com](http://www.syntellis.com)  
(847) 441-0022